Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 12/20 | 0.67 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.60 |
| ▸ | CDK1 | P06493 | 4/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.60 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.60 |
| ▸ | CDK4 | P11802 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13007969 | 0.89 | EIF2AK2 (0.60) | EIF2AK2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL3770545 | 0.76 | CDK1 (1.00) | EIF2AK2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL3770549 | 0.76 | CDK1 (1.00) | EIF2AK2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL6911490 | 0.75 | CDK2 (0.80) | EIF2AK2CDK4CDK2ABL1EGFR | |
| SCHEMBL878757 | 0.75 | AURKA (0.44) | EIF2AK2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL858414 | 0.74 | IMPDH2 (0.50) | CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2544992 | 0.74 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL14011244 | 0.72 | CDK4 (0.57) | EIF2AK2CDK4CDK2 | |
| SCHEMBL6106023 | 0.72 | CDK2 (0.56) | EIF2AK2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL857451 | 0.72 | ADORA2A (0.48) | CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173923-A1 | 4 (PYRROLOPYRIDINYL)PYRIMIDINYL-2-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173923-A1 | 4 (PYRROLOPYRIDINYL)PYRIMIDINYL-2-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| WO-2007107221-A1 | 4-(PYRROLOPYRIDINYL)PYRIMIDINYL-2-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173923-A1 | 4 (PYRROLOPYRIDINYL)PYRIMIDINYL-2-AMINE DERIVATIVES | MKI67, CDK4, CCNT1 | EIF2AK2 1680/4885CCNB2 24/4885CDK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.